Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P180047/S045

LIAISON QuantiFERON-TB Gold III; LIAISON Control QuantiFERON-TB Gold III; LIAISON QuantiFERON-TB Gold Plus II; LIAISON C

DiaSorin, Inc. · Decision date Aug 27, 2026

FDA DECISIONP180047/S045

What did the FDA approve?

FDA records P180047/S045 as a supplement to PMA P180047, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Aug 27, 2026.

FDA approval order statement

Approval of the addition of a three-tube blood collection configuration of the assay, introduction of the trade name LIAISON QuantiFERON-TB Gold III, LIAISON Control QuantiFERON-TB Gold III, and associated revisions to result interpretation and labeling.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Microbiology
Decision date
Aug 27, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P180047/S045
Regulatory pathway
PMA supplement
Product code
NCD
Decision code
APPR
Decision date
Aug 27, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: TEST, IMMUNITY, CELL MEDIATED, MYCOBACTERIUM TUBERCULOSIS.

Product code
NCD
FDA device class
3

For the original device and its historical approval scope, see PMA P180047. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P180047 · Original PMA

    LIAISON QuantiFERON - TB Gold Plus, LIAISON Control QuantiFERON - TB Gold Plus and LIAISON QuantiFERON Software

  2. P180047/S038 · Related supplement

    LIAISON QuantiFERON - TB Gold Plus and LIAISON XL Control QuantiFERON-TB Gold Plus

  3. P180047/S040 · Related supplement

    LIAISON QuantiFERON - TB Gold Plus and LIAISON Control QuantiFERON-TBGold Plus

  4. P180047/S037 · Related supplement

    LIAISON QuantiFERON - TB Gold Plus and LIAISON XL Control QuantiFERON-TB Gold Plus

  5. P180047/S041 · Related supplement

    LIAISON QuantiFERON-TB Gold Plus and LIAISON Control QuantiFERON-TB Gold Plus

  6. P180047/S039 · Related supplement

    LIAISON QuantiFERON TB Gold Plus II; LIAISON Control QuantiFERON TB Gold Plus II

  7. P180047/S044 · Related supplement

    LIAISON QuantiFERON - TB Gold Plus, LIAISON Control QuantiFERON - TB Gold Plus and LIAISON QuantiFERON Software

  8. P180047/S045 received

    Application receipt date recorded by FDA.

  9. P180047/S043 · Related supplement

    LIAISON QuantiFERON-TB Gold Plus; LIAISON XL Control QuantiFERON-TB Gold Plus; LIAISON QuantiFERON-TB Gold Plus II; LIAI

  10. P180047/S045 · FDA decision

    Real-Time Process

  11. P180047/S046 · Related supplement

    LIAISON QuantiFERON-TB Gold Plus II.

Timeline entries are records held by MedtechLedger for P180047. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P180047

Explore the linked device profile

Other records with product code NCD

Product / regulatory recordCompanyPathwayDecision dateSource
QiagenPMA supplementOct 14, 2026FDA
QiagenPMA supplementJan 23, 2026FDA
QiagenPMA supplementNov 21, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

DiaSorin, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1951 Northwestern Ave., Stillwater, MN, 55082

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records